Imatinib is one of the most recent medications used for the treatment of chronic 
myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). It is an 
orally administered protein-tyrosine kinase inhibitor, an enzyme which is 
produced by BCR-ABL fusion which results from translocation of 9:22 chromosome 
(Philadelphia chromosome). Imatinib blocks proliferation and induces apoptosis 
of BCR-ABL-expression in CML. Many side effects produced by imatinib have been 
documented but its induction of hepatotoxcity has been rarely reported. Only a 
few cases so far have been reported in the literature and almost all were in 
females. We describe another case of hepatotoxicity due to imatinib in a 17-year 
old female with clinical, laboratory and histopathological changes. The case 
described here suggests that imatinib may also induce immune hepatitis, in some 
patients.